Abstract
T cells can be genetically modified to target tumors through the expression of a chimeric antigen receptor (CAR). Most notably, CAR T cells have demonstrated clinical efficacy in hematologic malignancies with more modest responses when targeting solid tumors. However, CAR T cells also have the capacity to elicit expected and unexpected toxicities including: cytokine release syndrome, neurologic toxicity, "on target/off tumor" recognition, and anaphylaxis. Theoretical toxicities including clonal expansion secondary to insertional oncogenesis, graft versus host disease, and off-target antigen recognition have not been clinically evident. Abrogating toxicity has become a critical step in the successful application of this emerging technology. To this end, we review the reported and theoretical toxicities of CAR T cells and their management.
Original language | English (US) |
---|---|
Article number | 16011 |
Pages (from-to) | 16011 |
Number of pages | 1 |
Journal | Molecular Therapy - Oncolytics |
Volume | 3 |
DOIs | |
State | Published - Apr 20 2016 |
Externally published | Yes |
ASJC Scopus subject areas
- Molecular Medicine
- Oncology
- Cancer Research
- Pharmacology (medical)